Clinical Trial Update: Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates Nesvacumab (REGN910/SAR307746) in combination with aflibercept (Ziv-aflibercept) in patients with advanced solid tumors and the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Nesvacumab (nesvacumab)
• Ziv-aflibercept (ziv-aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED